Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 26, No 10 (April 1), 2008: pp. 1611-1618
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2006.10.4620

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bastit, L.
Right arrow Articles by Vansteenkiste, J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bastit, L.
Right arrow Articles by Vansteenkiste, J. F.
Related Articles
Right arrowRelated Article
Right arrowRelated Editorial
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Randomized, Multicenter, Controlled Trial Comparing the Efficacy and Safety of Darbepoetin Alfa Administered Every 3 Weeks With or Without Intravenous Iron in Patients With Chemotherapy-Induced Anemia

Laurent Bastit, An Vandebroek, Sevilay Altintas, Bernd Gaede, Tamás Pintér, Tamas S. Suto, Tony W. Mossman, Kay E. Smith, Johan F. Vansteenkiste

From the Centre Frédéric Joliot, Rouen, France; Ziekenhuisnetwerk Antwerpen and Campus Middelheim, Hemato-oncology, Antwerpen; University Hospital Antwerp, Edegem; University Hospital Gasthuisberg, Leuven, Belgium; Schwerpunktpraxis Haematology/Oncology (MediProjekt), Hannover, Germany; Petz Aladár Megyei Oktato Korhaz, Gyor, Hungary; Amgen (Europe) GmbH, Zug, Switzerland; and Amgen Ltd, Cambridge, United Kingdom

Corresponding author: Johan F. Vansteenkiste, MD, PhD, Respiratory Oncology Unit (Pulmonology), University Hospital Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium; e-mail: johan.vansteenkiste{at}uz.kuleuven.ac.be

Purpose The concomitant use of intravenous (IV) iron as a supplement to erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia is controversial. This study was designed to evaluate the efficacy and safety of darbepoetin alfa given with IV iron versus with local standard practice (oral iron or no iron).

Patients and Methods In this multicenter, randomized, open-label, phase III study, 396 patients with nonmyeloid malignancies and hemoglobin (Hb) less than 11 g/dL received darbepoetin alfa 500 µg with (n = 200) or without (n = 196) IV iron once every 3 weeks (Q3W) for 16 weeks.

Results The hematopoietic response rate (proportion of patients achieving Hb ≥ 12 g/dL or Hb increase of ≥ 2 g/dL from baseline) was significantly higher in the IV iron group: 86% versus 73% in the standard practice group (difference of 13% [95% CI, 3% to 23%]; P = .011). Fewer RBC transfusions (week 5 to the end of the treatment period) occurred in the IV iron group: 9% versus 20% in the standard practice group (difference of –11% [95% CI, –18% to –3%]; P = .005). Both treatments were well tolerated with no notable differences in adverse events. Serious adverse events related to iron occurred in 3% of patients in the IV iron group and were mostly gastrointestinal in nature.

Conclusion Addition of IV iron to darbepoetin alfa Q3W in patients with chemotherapy-induced anemia was well tolerated, resulting in an improved hematopoietic response rate and lower incidence of transfusions compared with darbepoetin alfa alone.

Supported by Amgen (Europe) GmbH (study 20040156; ClinicalTrials.gov identifier: NTC00135317).

Presented in part at the 42nd Annual Meeting of the American Society of Clinical Oncology, June 2-6, 2006, Atlanta, GA; the 11th Congress of the European Haematology Association, June 15-18, 2006, Amsterdam, the Netherlands; at the 31st European Society for Medical Oncology Congress, September 29-October 3, 2006, Istanbul, Turkey; at the 48th American Society of Hematology Annual Meeting, December 9-12, 2006, Orlando, FL; at the 43rd Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL; and at the 12th Congress of the European Hematology Association, June 7-9, 2007, Vienna, Austria.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Article

  • Randomized Trial of Intravenous Iron Supplementation in Patients With Chemotherapy-Related Anemia Without Iron Deficiency Treated With Darbepoetin Alfa
    Paolo Pedrazzoli, Antonio Farris, Salvatore Del Prete, Filomena Del Gaizo, Daris Ferrari, Clara Bianchessi, Giuseppe Colucci, Alberto Desogus, Teresa Gamucci, Alessandro Pappalardo, Giuseppe Fornarini, Paola Pozzi, Alessandra Fabi, Roberto Labianca, Francesco Di Costanzo, Simona Secondino, Enrico Crucitta, Federica Apolloni, Antonio Del Santo, and Salvatore Siena
    JCO 2008 26: 1619-1625 [Abstract] [Full Text]

Related Editorial

  • Should Intravenous Iron Be the Standard of Care in Oncology?
    Michael Auerbach
    JCO 2008 26: 1579-1581 [Full Text]


This article has been cited by other articles:


Home page
J Oncol Pharm PractHome page
A. C Fullmer and R. Miller
Retrospective review of hemoglobin and/or hematocrit levels with occurrence of thrombosis in cancer patients treated with erythropoiesis stimulating agents
Journal of Oncology Pharmacy Practice, September 1, 2009; 15(3): 167 - 173.
[Abstract] [PDF]


Home page
The OncologistHome page
M. Aapro
An Update on Twenty Years of Anemia Management with Erythropoiesis-Stimulating Agents in Nephrology and Oncology/Hematology
Oncologist, September 1, 2009; 14(suppl_1): 1 - 5.
[Full Text] [PDF]


Home page
Ann OncolHome page
D. Scrijvers, F. Roila, and On behalf of the ESMO Guidelines Working Group
Erythropoiesis-stimulating agents in cancer patients: ESMO Recommendations for use
Ann. Onc., May 1, 2009; 20(suppl_4): iv159 - iv161.
[Full Text] [PDF]


Home page
Journal of Pharmacy PracticeHome page
S. B. Silverstein, J. A. Gilreath, and G. M. Rodgers
Intravenous Iron Therapy: A Summary of Treatment Options and Review of Guidelines
Journal of Pharmacy Practice, December 1, 2008; 21(6): 431 - 443.
[Abstract] [PDF]


Home page
ASH Education BookHome page
J. W. Adamson
The Anemia of Inflammation/Malignancy: Mechanisms and Management
Hematology, January 1, 2008; 2008(1): 159 - 165.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online